Spravato (esketamine)
What is Spravato?
SPRAVATO® is the only FDA-approved treatment used as monotherapy or in conjunction with an oral antidepressant for adults with treatment-resistant depression (MDD with inadequate response to at least 2 oral antidepressants of adequate dose and duration)
SPRAVATO® is a unique treatment approach that delivers:
Results as early as 24 hours and out to 28 days
Long-term safety and efficacy out to 5 years
Indications
SPRAVATO® is for use in combination with an oral antidepressant for depressive symptoms in adults with MDD with acute suicidal ideation or behavior (MDSI)
SPRAVATO® is a nasal spray that is administered under the supervision of a healthcare provider.
SPRAVATO® is only administered in a medically supervised healthcare setting that is certified under the SPRAVATO® REMS.
How it works
SPRAVATO® is different because it targets glutamate, the most abundant excitatory neurotransmitter in the brain
The primary antidepressant activity of SPRAVATO® is not believed to directly involve inhibition of serotonin or norepinephrine reuptake.
The precise mechanism of action (MOA) is unknown.1,3-6
SPRAVATO® is an NMDA receptor antagonist. An NMDA receptor is an ionotropic glutamate receptor.1
NMDA=N-methyl-D-aspartate.
SPRAVATO® hypothesized MOA.